Brief: Sk Biopharmaceuticals Q2 Operating Loss 19 Billion Won, Up 52.7% From Year Earlier
SK Biopharmaceuticals Co Ltd 326030.KS :
* SK BIOPHARMACEUTICALS: Q2 OPERATING LOSS 19 BILLION WON,
UP
52.7% FROM YEAR EARLIER
Source text for Eikon: ID:
Further company coverage: 326030.KS
Recent news on SK Biopharmaceuticals Co
See all newsInsilico Medicine hits 3-week high on SK Biopharmaceuticals tie-up
Signs Joint Rd Partnership Agreement With Insilico Medicine
Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
Announces Pharmaceutical Supply Contract